SAN Share Price

Open 77.51 Change Price %
High 78.16 1 Day -1.16 -1.49
Low 76.71 1 Week -0.58 -0.75
Close 76.91 1 Month 2.52 3.39
Volume 1231354 1 Year 5.41 7.57
52 Week High 79.07
52 Week Low 62.50
SAN Important Levels
Resistance 2 78.25
Resistance 1 77.70
Pivot 77.26
Support 1 76.12
Support 2 75.57
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
ALADO 0.05 0.00%
AVQ 0.25 4.17%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
EPA France Top Gainers Stocks
CFI 1.71 61.32%
CFI 1.71 61.32%
CFI 1.71 61.32%
CFI 1.71 61.32%
SFCA 2.29 28.65%
ALBUD 5.22 18.10%
APAM 33.78 15.72%
APAM 33.78 15.72%
MLLOI 3.80 15.15%
DEXB 17.47 13.89%
EPA France Top Losers Stocks
MLWTT 1.70 -41.58%
MLONE 0.47 -18.97%
RUSAL 8.25 -12.97%
MLHIN 142.00 -9.09%
ALHEO 1.11 -7.50%
TVRB 30.11 -5.91%
VCT 56.01 -4.78%
VCT 56.01 -4.78%
VCT 56.01 -4.78%
ALWEB 10.18 -4.32%

Sanofi (EPA: SAN)

SAN Technical Analysis 4
As on 16th Jan 2017 SAN Share Price closed @ 76.91 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 72.73 & Buy for SHORT-TERM with Stoploss of 75.75 we also expect STOCK to react on Following IMPORTANT LEVELS.
SAN Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
SAN Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drugs - Generic
Offical website
SAN Address
54, Rue La Bo
Paris, 75008
Phone: 33 1 53 77 40 00
Interactive Technical Analysis Chart Sanofi ( SAN EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on Sanofi
SAN Business Profile
Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in three segments: Pharmaceuticals, Human Vaccines, and Animal Health. Its products include Lantus and Apidra analogs of human insulin; Insuman human insulin solutions and suspensions; Amaryl, a sulfonylurea; BGStar, iBGStar, and MyStar Extra blood glucose meters; enzyme replacement therapies, such as Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aldurazyme, for mucopolysaccharidosis Type I; Aubagio, a immunomodulator for multiple sclerosis; Taxotere, a taxane derivative for cancers; Eloxatine for colorectal cancer; and Jevtana for prostate cancer. The company’s products also comprise thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines, including Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. It also offers Renagel/Renvela for patients with chronic kidney disease on dialysis to treat high phosphorus levels; Synvisc and Synvisc-One viscosupplements to treat pain associated with osteoarthritis; and pediatric and influenza, adult and adolescent booster, meningitis and pneumonia, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products; and generic medicines. Sanofi distributes its products through its sales force, as well as through physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. It has strategic alliances with Bristol-Myers Squibb, Regeneron, Warner Chilcott, and Regulus Therapeutics Inc., as well as a strategic collaboration with UCB S.A. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1970 and is headquartered in Paris, France.